agip,
It is interesting and as you know shorting is a dangerous business.
Another stock showing a taste of human nature is Valeant (VRX) down another 6% or $10 to $151. One analyst lowered their price target from $300 to $200. I can't help but think that target will come down some more. VRX trades at 87 times last year's earnings and the business model is based on acquisitions and pharmaceutical prices hikes.
Also, YUM's business deteriorates so to stop the slide breaks out its China business as a spin off. I am sure it is good business for the investment banks but a shell game move for YUM. Of course you will hear the usual spin about how the move will increase "shareholder value."
Strange things these days.
Igy